Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis : analysis of pooled data from the randomized trials SOLO 1 and SOLO 2

Show full item record



Permalink

http://hdl.handle.net/10138/325834

Citation

Cork , M J , Eckert , L , Simpson , E L , Armstrong , A , Barbarot , S , Puig , L , Girolomoni , G , de Bruin-Weller , M , Wollenberg , A , Kataoka , Y , Remitz , A , Beissert , S , Mastey , V , Ardeleanu , M , Chen , Z , Gadkari , A & Chao , J 2020 , ' Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis : analysis of pooled data from the randomized trials SOLO 1 and SOLO 2 ' , Journal of Dermatological Treatment , vol. 31 , no. 6 , pp. 606-614 . https://doi.org/10.1080/09546634.2019.1612836

Title: Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis : analysis of pooled data from the randomized trials SOLO 1 and SOLO 2
Author: Cork, Michael J.; Eckert, Laurent; Simpson, Eric L.; Armstrong, April; Barbarot, Sebastien; Puig, Luis; Girolomoni, Giampiero; de Bruin-Weller, Marjolein; Wollenberg, Andreas; Kataoka, Yoko; Remitz, Anita; Beissert, Stefan; Mastey, Vera; Ardeleanu, Marius; Chen, Zhen; Gadkari, Abhijit; Chao, Jingdong
Other contributor: University of Helsinki, Department of Dermatology, Allergology and Venereology


Date: 2020-08-17
Language: eng
Number of pages: 9
Belongs to series: Journal of Dermatological Treatment
ISSN: 0954-6634
DOI: https://doi.org/10.1080/09546634.2019.1612836
URI: http://hdl.handle.net/10138/325834
Abstract: Background: Atopic dermatitis (AD) profoundly affects quality of life (QoL). Dupilumab significantly improves clinical outcomes, is well tolerated, and approved to treat inadequately controlled moderate-to-severe AD in adults; however, its effect on patient-reported outcomes (PROs) is not fully characterized. Objective: To evaluate the impact of dupilumab on patient-reported AD symptoms and QoL. Methods: Pooled data were analyzed from two identically designed phase 3 studies, LIBERTY AD SOLO 1 (NCT02277743) and SOLO 2 (NCT02277769), assessing the following PROs: Peak Pruritus Numerical Rating Scale (NRS), Pruritus Categorical Scale, SCORing AD (SCORAD), Dermatology Life Quality Index (DLQI), Patient-Oriented Eczema Measure (POEM), Hospital Anxiety and Depression Scale (HADS), five-dimension EuroQoL questionnaire (EQ-5D), and patient-assessed disease status and treatment effectiveness. Results: Dupilumab rapidly improved (vs. placebo) Peak Pruritus NRS scores by day 2 (p <.05), anxiety and depression (HADS), and QoL (DLQI) by week 2, and maintained through week 16 (p <.0001). At week 16, more dupilumab-treated than placebo-treated patients reported improvement in SCORAD itch and sleep, and no pain/discomfort (EQ-5D) (p <.0001). Limitations: Cultural differences of translated PROs. Conclusion: Dupilumab had a significant, positive impact on AD symptoms, including itch, sleep, pain, anxiety and depression, and QoL in adults with moderate-to-severe AD.
Subject: Atopic dermatitis
dupilumab
patient-reported outcomes
quality of life
ADULT PATIENTS
HOSPITAL ANXIETY
GUIDELINES
MANAGEMENT
ECZEMA
MECHANISMS
DISEASE
PLACEBO
BURDEN
CARE
3141 Health care science
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Dupilumab_impro ... ty_of_life_in_moderate.pdf 1.415Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record